Hillel Bachrach is a dynamic executive entrepreneur, with over 30 years of hands-on management and directorship with all aspects of successful commercial global introductions of new, innovative, and revolutionary medical technologies. His work has lead to significant sustained and profitable growth providing direct and positive impact on the valuation of the corresponding enterprise. Bachrach is the Managing Partner of 20/20 HealthCare Partners LLC.
20/20 HCP owns and provides equity financing for promising growth businesses as well as for buyouts or re-capitalizations of companies specializing in the HealthCare IT & Diagnostic Imaging Devices. Bachrach co-founded ESC Medical Systems, the first medical laser/flash lamp companies addressing cosmetic applications. Took it public with a NASDQ IPO in 1996 (ESCF). ESC Medical later changed its name to Lumenis (LMNS). (Lumenis was acquired June 2015 by XIO Group for $510million).
In 1999 Bachrach co-founded MSq, Ltd. (aka Alma Laser), another innovator in the medical laser field. Boston based TA Associates purchased 66% of Alma in 2006 for $130million, and Fuson, a Chinese pharmaceutical company, purchased the entire company in 2013 foe $230million. Bachrach obtained VC funding for the turnaround of Orex Computerized Radiography, a manufacturer of Computerized Radiography (CR) systems and software, where he served as the CEO from 2001. Orex was sold to Eastman Kodak in 2005. In 2006 20/20 HCP acquired a majority ownership in Viztek, a provider of HealthCare IT, hardware and software solutions; Bachrach serves as Viztek executive Chairman. Viztek 2014 sales reached a profitable $55M. In October 2015 Viztek was acquired by the Japanese conglomerate, Konica Minolta.
He also led various funding rounds of Corindus, a company specialized in Robotics for the CathLab. Corindus obtained a strategic investment from Phillips Medical. Through a reverse merger, in September 2014, Corindus went public on NASDAQ, (CVRS). In April of 2015 Corindus, (CVRS), started to be traded on NYSE. Also in September 2014, additional portfolio company of Mr. Bachrach, Vascular Biogenics Laboratories, went public on NASDAQ, (VBLT). He has also served as the President of Odin Medical Technologies, Inc. (sold to Medtronic in 2006). Bachrach helped found UltraSPECT, Ltd, in 2001 the leader in providing sophisticated software solutions for dose and procedure time reduction for nuclear medicine procedures. Other 20/20 HCP MedTech investments/ directorships include SRS Medical, a leader in the specialty Urology marketplace; Eight Spoke, provider of IT solutions to the Pharma industry and ImmunoExcite, a biopharma company focused on developing a cancer therapy based on an innovative innate-immunotherapy platform.
In 2015 20/20 HCP participated with Polaris Venture Fund in funding a promising biotech delivery company, SQZ Biotechnology. SQZ has been appointed as one of the Fierce 15 Biotech companies of 2015 by Fierce Biotech! And in 2014 as the runner up to CRISPR in the most promising new biotech technologies. During the last few years Mr. Bachrach divested his activities to two new avenues, New Media & Lifestyle. On the Media side he co-led various investment rounds in Zixi – a leading enabler of flawless broadcast quality HDTV over the Internet. Velocomp is Mr. Bachrach’s latest investment. Velocomp is the developer of innovative and advanced cycling Power Meters. He received his MBA from the Kellogg Graduate School of Management in 1976 and a B.S in Electrical Engineering from Technion Israeli Institute of Technology in 1971.
Christine is a serial Entrepreneur, Founder & Former CEO of two Life Science Companies: INTICA Biomedical (Personalized Medicine/Cancer) and TARIS Biomedical. TARIS (www.tarisbiomedical.com), acquired by Allergan in 2014,was co-founded with Prof. Michael Cima and Prof. Robert Langer from MIT, Cambridge, MA. Christine is a Venture Partner and Entrepreneur in Residence with 20/20 HealthCare Partners, a private global investment group. Previously, Christine was with Merck & Co. in Whitehouse Station, NJ, where she was leading worldwide Commercialization for Inflammation, Neuroscience and Cardiovascular Products. Prior to Merck & Co., Christine assumed various R&D, Business Management and Commercialization Functions at Hoffmann- La Roche in Basel, Switzerland. Christine got her Degree’s in Medical Technology & Immunochemistry (Biochemistry) from the Institute for Hygiene and Infectious Diseases / Medical School of the University of Saarbrücken, Germany.
Christine mentors Entrepreneurs/new Technology start-up’s at the MIT Deshpande Center. She serves on the Board of the Beth Israel Deaconess Medical Center (BIDMC) and on the Advisory Board of the BIDMC Cancer Research Center. Christine is a German native with German Jewish & Catalan family background from Barcelona, Spain. She grew up in the Netherlands, Belgium, France and Germany. Christine lives with her husband and two children in Lexington, MA. Christine is a dedicated “Yogi” and enjoys outdoor activities including sailing, running and skiing.
Jonathan Fleming is the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology based investments He is also a General Partner of the Korea-Seoul Life Science Fund.
Mr. Fleming has been in the investment business for over twenty seven years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming has also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Mr. Fleming is a director of several private companies including Dicerna Pharmaceuticals, Lab Partners, Greenlight and Railrunner. He is also a director of Leerink Swann, a Boston based investment bank specializing in healthcare companies. In addition, Mr. Fleming is a Senior Lecturer at the MIT Sloan School of Business, a Lecturer at the Harvard Medical School, a Trustee of the Museum of Science in Boston, and a Member of the Board of NEHI, a healthcare oriented think tank and policy advocacy group. Mr. Fleming is on the Scientific Advisory Board of the Massachusetts Life Science Center, and is a member of the Barnett Institute Advisory Board as well as the Chancellor’s Commercialization Advisory Board of the University of Texas System. Mr. Fleming holds a Master’s degree in Public Administration from Princeton University and a Bachelor of Arts degree from the University of California, Berkeley.
Walter M. Capone
Walter is an accomplished, global Biotech/Pharma leader with a twenty year track record of accelerating breakthrough
science, drug development and commercialization. His therapeutic experience spans the immunology, oncology and infectious disease areas. From 2010-2016, he was CEO & President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), where he transformed the Foundation to leverage industry
experience, academic research and FDA collaborations, resulting in 50% revenue growth to >$30M, a record 6 new
drugs approved/launched and a >4-fold expansion in academic/industry partnerships. In his roles as SVP
Commercial Operations, VP Commercial Development, and Division Manager for Progenics, Triangle Pharmaceuticals,
Trimeris, BMS, Wyeth and Lederle, Walter has led the development and launch of over 18 novel drugs including
FUZEON®, EMTRIVA®, TEQUIN®, ZERIT®, VIDEX®, and ZOSYN®.
Walter obtained his M.B.A. from Columbia University and B.A. from Brown University.
Ronny Vinasco Bachrach
Ronny Bachrach’s experience includes childhood development, as well as research of Alzheimer’s Disease and Semantic Dementia. Bachrach graduated cum laude from Colby College with distinction in psychology.